查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466028

Castleman氏病治疗市场：按疾病类型、适应症、治疗方法和应用分类 - 全球预测 2024-2030

Castleman Disease Treatment Market by Disease Type, Indication, Treatment, Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

Castleman氏病治疗市场规模预计2023年为2.9433亿美元，2024年达到3.3415亿美元，预计2030年将达到7.1987亿美元，复合年增长率为13.62%。

Castleman氏病的治疗涉及专门的医疗治疗，以治疗一种称为Castleman氏病的罕见疾病。此疾病的特征是身体淋巴结中细胞过度生长，引起从发烧、疲劳到异常体重减轻等症状。近年来，包括Castleman氏病在内的罕见疾病的盛行率增加，因此需要增加治疗选择。多年来，我们对Castleman氏病的了解不断加深，从而促进了标靶治疗的发展。正在进行的研究重点是识别生物标记、了解潜在的病理学和发现新的治疗方法。Castleman氏病的几种治疗方法已获得孤儿药资格，这为製药公司开发罕见疾病的治疗方法提供了奖励。然而，药物开发成本高昂、治疗选择有限以及严格的监管合规性阻碍了治疗的扩展。医疗保健专业人员、研究人员和倡导团体正在全球范围内合作，以改善Castleman氏病的诊断、管理和治疗。

主要市场统计
基准年[2023] 2.9433亿美元
预测年份 [2024] 33415万美元
预测年份 [2030] 71987万美元
复合年增长率（%） 13.62%

疾病类型：多中心Castleman氏病有可能导致全身器官衰竭，需要快速制定治疗策略。

多中心Castleman氏病(MCD) 是一种导致患者身体多个区域淋巴结肿大的疾病。多中心Castleman氏病有三种症状：多发性神经炎、器官肿大、内分泌疾病、M蛋白、皮肤改变(POEMS)相关的MCD、人类疱疹病毒8(HHV-8)相关的MCD和特发性MCD 。多中心Castleman氏病的治疗通常涉及药物和其他治疗方法来抑制细胞过度生长。特定治疗方法还取决于疾病的严重程度以及患者感染疾病感染疾病人类免疫力缺乏病毒 (HIV)、人类疱疹病毒 8 (HHV-8) 或两者。单中心Castleman氏病(UCD) 是一种影响一个淋巴结的疾病，通常位于胸部或腹部。单中心Castleman氏病可以透过手术切除受影响的淋巴结来治疗。

增加血管瘤肝血管瘤淋巴结病例的Castleman氏病治疗选择

肝血管瘤瘤样淋巴结增生与长期发烧、贫血、体重减轻、脾肿大和高丙种球蛋白血症有关。肝血管瘤淋巴球错构瘤或假性淋巴瘤最常见于乳房，常被误认为是伴随淋巴瘤样组织的胸腺肿瘤。这是一种罕见的疾病，经常使用免疫调节疗法。 Castleman 肿瘤是一种罕见的纵膈淋巴结增生，类似胸腺瘤。典型的组织学特征包括结节中淋巴球的洋葱皮样排列和具有明显毛细血管增殖的异常脉管系统。巨大良性淋巴瘤是发生在大肠中最常见的非上皮性良性肿瘤。通常在直肠中观察到单一圆形息肉，呈红紫色或灰色，直径从几毫米到 3 至 4 公分不等。巨大淋巴结增生是一种病因不明的非肿瘤性淋巴增生性疾病，通常发生在胸部。这种疾病的型态辨识是基于各种组织学特征的组合。淋巴结血管肌瘤性错构瘤（AMH-LN）是指平滑肌、血管、胶体基质和脂肪细胞的异常良性增生。

治疗方法化疗的进步正在增加Castleman氏病治疗方案的采用。

抗病毒药物用于针对有害病毒。抗病毒药物用于缓解疾病症状。化疗是指使用药物和化疗来杀死患者体内快速生长的癌细胞。低剂量单药化疗，例如每日口服Etoposide或间歇性Etoposide或长春花碱，已用于治疗 MCD。皮质类固醇是一种强效发炎药，可以缓解疾病症状。全身给予皮质类固醇可以缓解症状，但不能预测肿瘤缩小。免疫疗法利用人体的自​​然防御来对抗疾病。单株抗体是实验室製造的蛋白质，仅与一种致病抗原结合。利Rituximab治疗对 HHV-8 相关 MCD 非常有效。有些 HIV 感染者需要接受Rituximab抗逆转录病毒治疗 (ART)。放射线治疗是一种利用放射线杀死癌细胞并缩小肿瘤的癌症治疗方法。对于单中心Castleman氏病，放射线治疗是一种有效的治疗选择，且反应率较高。

门诊手术中心是提供最佳患者照护的首选

门诊手术中心 (ASC) 是一个现代化的医疗设施，旨在提供当天的手术治疗，包括诊断和预防程序。这些中心由于医疗效率高并且减少了治疗预约的等待时间，在Castleman氏病的治疗中越来越普及。由于疾病管理的复杂性与护理强度有关，医院部门仍然是Castleman氏病治疗的主要贡献者。

区域洞察

美洲，特别是美国和加拿大，拥有相对完善的诊断和治疗罕见疾病（包括Castleman氏病）的基础设施。有专门研究Castleman氏病的专门医疗中心和专家，患者倡导团体和研究组织为提高诊断和治疗的认识和进步做出了贡献。儘管与其他地区相比，亚洲Castleman氏病的治疗机会有限，但政府对医疗保健发展的投资极大地推动了针对这种罕见疾病的更有针对性的治疗方法。该地区的主要城市提供先进的诊断和治疗方案，而规模较小的学术机构正在中国、日本和印度大力投资研发活动。在欧洲，各国政府正在促进相关人员在医疗保健和研究工作方面的合作，以帮助治疗Castleman氏病。欧洲药品管理局正在努力审查和核准改进的药物，以改善该地区Castleman氏病者的治疗提供和获得机会。

FPNV定位矩阵

FPNV 定位矩阵对于评估Castleman氏病治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对Castleman氏病治疗市场中供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.CastlemanCastleman氏病治疗市场的市场规模与预测为何？

Castleman氏病治疗市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些？

3.CastlemanCastleman氏病治疗市场的技术趋势和法规结构是什么？

4.CastlemanCastleman氏病治疗市场主要厂商的市场占有率是多少？

5. 进入Castleman氏病治疗市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • Castleman氏病的盛行率和有效疾病管理的必要性
      • 为Castleman氏病治疗提供孤儿药指定和核准
      • 患者支持团体的兴起和卡斯尔曼治疗的意识计划
    • 抑制因素
      • Castleman氏病药物开发的复杂性
    • 机会
      • 新Castleman氏病治疗方法的开发不断取得进展
      • Castleman氏病个人化医疗新趋势
    • 任务
      • 缺乏标准化的治疗通讯协定
  • 市场区隔分析
    • 疾病类型：由于潜在的全身器官衰竭，需要快速开发多中心Castleman氏病的治疗策略
    • 适应症：越来越多采用Castleman氏病治疗肝血管瘤淋巴瘤病例
    • 治疗：化疗的进步扩大了Castleman氏病治疗方案的采用
    • 用途：透过提供最佳的患者照护来优先考虑门诊手术中心
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章Castleman氏病治疗市场：依疾病类型

  • 多中心Castleman氏病
  • 单中心Castleman氏病

第七章Castleman氏病治疗市场（按适应症）

  • 血管滤泡淋巴结增生
  • 肝血管瘤管
  • 卡斯特曼瘤
  • 巨大良性淋巴瘤
  • 巨大淋巴结增生
  • 淋巴错构瘤

第八章Castleman氏病治疗市场（依治疗）

  • 抗病毒药物
  • 化疗
  • 皮质类固醇
  • 免疫疗法
  • 单株抗体
  • 放射治疗

第九章Castleman氏病治疗市场：依应用分类

  • 门诊手术中心
  • 医院

第10章 美洲Castleman氏病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太Castleman氏病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲Castleman氏病治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • FDA核准托珠单抗生物相似药 Tofidence
    • 中外製药Actemra的额外适应症在日本获得核准，用于治疗与癌症治疗相关的细胞激素释放综合征
    • Medable 与 Every Cure 合作，加速罕见疾病治疗方法的发现
  • 战略分析和建议

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-4312A385A340

[196 Pages Report] The Castleman Disease Treatment Market size was estimated at USD 294.33 million in 2023 and expected to reach USD 334.15 million in 2024, at a CAGR 13.62% to reach USD 719.87 million by 2030.

Castleman disease treatment involves a specialized healthcare procedure to manage a rare illness called Castleman disease, which is characterized by the overgrowth of cells in the body's lymph nodes, causing a variety of symptoms from fever and fatigue to abnormal weight loss. Recent years have observed an increased prevalence of rare diseases, including Castleman disease, necessitating enhanced treatment options. The understanding of Castleman disease has advanced over the years, leading to the development of targeted therapies. Ongoing research focuses on identifying biomarkers, understanding the underlying pathophysiology, and discovering novel treatment options. Some treatments for Castleman disease have received orphan drug designation, which provides incentives for pharmaceutical companies to develop therapies for rare diseases. However, the high cost of drug development, limited treatment options, and strict regulatory compliance impede the expansion of treatment. Healthcare professionals, researchers, and advocacy groups are collaborating on a global scale to improve the diagnosis, management, and treatment of Castleman disease.

KEY MARKET STATISTICS
Base Year [2023] USD 294.33 million
Estimated Year [2024] USD 334.15 million
Forecast Year [2030] USD 719.87 million
CAGR (%) 13.62%

Disease type: Need for rapid deployment of treatment strategies for multicentric Castleman's disease due to the chances of systemic organ failure

Multicentric Castleman's disease (MCD) refers to the disease condition that causes lymph node enlargement in multiple regions of the patient's body. There are three categories of MCD-Polyneuropathy, organomegaly, endocrinopathy, M proteins, and skin changes (POEMS)-associated MCD, human herpesvirus-8 (HHV-8)-associated MCD, and idiopathic MCD. Treatment for multicentric Castleman disease generally involves medicines and other therapies to control cell overgrowth. Specific treatment may also depend on the extent of the disease and whether the patient has human immunodeficiency virus infection (HIV), human herpesvirus-8 (HHV-8) infection, or both. Unicentric Castleman's disease (UCD) refers to a disorder that affects a single lymph node in the patient's body, usually in the chest or abdomen. Unicentric Castleman disease can be treated by surgically removing the diseased lymph node.

Indication: Rising adoption of Castlemann's disease treatment options for tackling angiomatous lymphoid cases

Angiofollicular lymph node hyperplasia is associated with prolonged fever, anemia, weight loss, splenomegaly, and hypergammaglobulinemia. Angiomatous lymphoid hamartomas or pseudolymphomas have been reported most commonly within the chest and are usually mistaken for thymic tumors of lymphomatous tissue. It is a rare manifestation where immunomodulatory treatment is often utilized. Castleman tumor is an unusual mediastinal lymph node hyperplasia that resembles thymoma. The characteristic histologic characteristics include an onion skin arrangement of the lymphocytes in nodules and an unusual vasculature with marked capillary proliferation. Giant benign lymphoma is the most common non-epithelial benign tumor occurring in the large intestine. It is usually observed in the rectum as a single reddish-purple or grey, rounded polyp varying in diameter from a few millimeters to 3-4 centimeters. Giant lymph node hyperplasia is a nonneoplastic lymphoproliferative disorder of unknown etiology that is usually observed in the chest. The morphological recognition of this disease is based on a combination of various histological features. Angiomyomatous hamartoma of lymph nodes (AMH-LN) refers to an unusual benign proliferation of smooth muscle, blood vessels, collagenous stroma, and adipocytes.

Treatment: Advancements in chemotherapy treatments leading to expanding adoption of Castleman disease treatment options

Antiviral medications are used to target harmful viruses. The antiviral drugs are used to ease disease symptoms. Chemotherapy refers to the practice of utilizing a drug or chemical treatment to kill fast-growing cancer cells in a patient's body. Low-dose single-agent chemotherapy treatment options, such as daily oral etoposide59 or intermittent etoposide or vinblastine, have been utilized for MCD. Corticosteroids are powerful anti-inflammatory drugs that can mitigate disease symptoms. Systemic corticosteroids can provide symptomatic relief but do not predictably reduce tumor size. Immunotherapy takes advantage of the body's natural defenses to fight the disease. Monoclonal antibodies refer to proteins made in a laboratory that bind to one pathogenic antigen only. In HHV-8-associated MCD, treatment with rituximab is highly effective. For some patients with HIV infection, antiretroviral therapy (ART) should be included with the rituximab. Radiation therapy refers to a cancer treatment that uses bursts of radiation to target and kill cancer cells and shrink tumors. In unicentric Castleman disease, radiotherapy radiation therapy is a viable treatment option because of its high response rates.

Application: Preference for ambulatory surgical centers due to provision of optimum patient care

Ambulatory surgical centers (ASCs) refer to modern medical facilities that aim to provide same-day surgical care, including diagnostic and preventive procedures. These centers have gradually become popular for the treatment of Castleman disease due to their perceived medical efficiency and the reduced waiting times involved in scheduling a treatment. The hospital segment continues to remain a significant contributor to Castleman disease treatment owing to the intensity of care that comes with the complex nature of disease management.

Regional Insights

The Americas, particularly the U.S. and Canada, has a relatively well-established infrastructure for rare disease diagnosis and treatment, including Castleman disease. There are specialized medical centers and experts focused on the condition, and patient advocacy groups and research institutes have contributed to the awareness and advancements in diagnosis and treatment. In Asia, access to castle treatment is limited when compared to the other regions; however, the government investment in healthcare development has significantly strived toward a more focused approach to rare diseases. Major cities in the region offer advanced diagnostic and treatment options, and small-scale academic institutes in China, Japan, and India are investing heavily in R&D activities. In Europe, the government promotes stakeholder cooperation in healthcare and research activities, benefiting the treatment of Castleman disease. The European Medicines Agency has been working on reviewing improved medications and approving them to elevate the provision and access to Castleman treatment to patients in the region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Castleman Disease Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Castleman Disease Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Castleman Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Amgen Inc., Artiva Biotherapeutics, Inc., Bayer AG, Bio-Rad Laboratories, Inc., Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Celltrion Healthcare Co.,Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals S.A., Johnson & Johnson Services, Inc., LGM Pharma, Merck & Co., Inc., Novartis AG, Octapharma AG, Pfizer, Inc., Recordati Group Company, Recordati S.p.A., Sanofi S.A., Sartorius AG, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Castleman Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Multicentric Castleman's Disease
    • Unicentric Castleman's Disease
  • Indication
    • Angiofollicular Lymph Node Hyperplasia
    • Angiomatous Lymphoid
    • Castleman Tumor
    • Giant Benign Lymphoma
    • Giant Lymph Node Hyperplasia
    • Hamartoma of the Lyphatics
  • Treatment
    • Antiviral Drugs
    • Chemotherapy
    • Corticosteroids
    • Immunotherapy
    • Monoclonal Antibodies
    • Radiation Therapy
  • Application
    • Ambulatory Surgical Centers
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Castleman Disease Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Castleman Disease Treatment Market?

3. What are the technology trends and regulatory frameworks in the Castleman Disease Treatment Market?

4. What is the market share of the leading vendors in the Castleman Disease Treatment Market?

5. Which modes and strategic moves are suitable for entering the Castleman Disease Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of Castleman disease and the need for effective disease management
      • 5.1.1.2. Provision of orphan drug designation and approvals for Castleman disease treatments
      • 5.1.1.3. Rise of patient advocacy groups and awareness programs for Castleman treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities in the drug development for Castleman disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in the development of new Castleman disease treatment
      • 5.1.3.2. Emerging trend of personalized medicine for Castleman disease treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Lack fo standardized treatment protocols
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease type: Need for rapid deployment of treatment strategies for multicentric Castleman's disease due to the chances of systemic organ failure
    • 5.2.2. Indication: Rising adoption of Castlemann's disease treatment options for tackling angiomatous lymphoid cases
    • 5.2.3. Treatment: Advancements in chemotherapy treatments leading to expanding adoption of Castleman disease treatment options
    • 5.2.4. Application: Preference for ambulatory surgical centers due to provision of optimum patient care
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Castleman Disease Treatment Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Multicentric Castleman's Disease
  • 6.3. Unicentric Castleman's Disease

7. Castleman Disease Treatment Market, by Indication

  • 7.1. Introduction
  • 7.2. Angiofollicular Lymph Node Hyperplasia
  • 7.3. Angiomatous Lymphoid
  • 7.4. Castleman Tumor
  • 7.5. Giant Benign Lymphoma
  • 7.6. Giant Lymph Node Hyperplasia
  • 7.7. Hamartoma of the Lyphatics

8. Castleman Disease Treatment Market, by Treatment

  • 8.1. Introduction
  • 8.2. Antiviral Drugs
  • 8.3. Chemotherapy
  • 8.4. Corticosteroids
  • 8.5. Immunotherapy
  • 8.6. Monoclonal Antibodies
  • 8.7. Radiation Therapy

9. Castleman Disease Treatment Market, by Application

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals

10. Americas Castleman Disease Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Castleman Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Castleman Disease Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves Tocilizumab Biosimilar Tofidence
    • 13.3.2. Chugai Obtains Approval for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Therapy in Japan
    • 13.3.3. Medable Partners with Every Cure to Accelerate Discovery of Treatments for Rare Diseases
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CASTLEMAN DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CASTLEMAN DISEASE TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. CASTLEMAN DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. CASTLEMAN DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CASTLEMAN DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MULTICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MULTICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY UNICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY UNICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOMATOUS LYMPHOID, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOMATOUS LYMPHOID, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CASTLEMAN TUMOR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CASTLEMAN TUMOR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT BENIGN LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT BENIGN LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT LYMPH NODE HYPERPLASIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT LYMPH NODE HYPERPLASIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HAMARTOMA OF THE LYPHATICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HAMARTOMA OF THE LYPHATICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 78. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 85. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 86. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 87. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 114. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 121. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 122. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 123. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 129. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 130. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 131. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 138. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 139. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 146. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 147. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 154. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 155. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 162. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 169. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 170. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 171. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 178. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 185. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 186. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 187. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 193. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 194. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 195. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 202. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 203. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 204. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 219. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 220. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 221. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 227. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 228. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 229. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 236. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 237. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 244. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 245. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 246. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 252. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 253. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 260. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 261. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 267. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 268. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 269. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 276. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 278. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 284. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 285. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 290. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 291. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 292. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 293. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 294. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 298. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 299. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 300. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 301. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 302. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 305. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 306. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 307. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 308. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 309. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 310. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 314. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 315. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 316. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 317. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 318. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 322. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDI